Drug Details
| General Information of the Drug (ID: DR7618) | ||||
|---|---|---|---|---|
| Name |
Mitotane
|
|||
| Synonyms |
mitotane; 53-19-0; Mitotan; Lysodren; Chloditan; o,p'-DDD; Chlodithane; Khlodithan; Chlodithan; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; 2,4'-Ddd; Mitotano; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene; NCI-C04933; o,p'-TDE; 2,4'-Dichlorodiphenyldichloroethane; 1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene; o,p'-Dichlorodiphenyldichloroethane; Benzene, 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]-; 2,4'-Dichlorophenyldichlorethane; CB 313; NSC 38721; 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane; 2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane; 1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane; NSC38721; 1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane; 2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane; CB-313; NSC-38721; 2,4'-DDD;o,p'-DDD; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-; Ethane, 2-(o-chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloro-; Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)-; MFCD00000850; Mitotanum [INN-Latin]; o,p-Tde; NCGC00015226-07; 1-chloro-4-[2,2-dichloro-1-(2-chlorophenyl)ethyl]benzene; Mitotanum; DSSTox_CID_372; Mitotano [INN-Spanish]; DSSTox_RID_75548; DSSTox_GSID_20372; 2,4'-(2,2-dichloroethane-1,1-diyl)bis(chlorobenzene); Opeprim; 2,4 -Dichlorodiphenyldichloroethane; Mitotane (Lsodren); CB313; DDD, o,p'-; CAS-53-19-0; Lysodren (TN); SMR000326696; CCRIS 4397; HSDB 3240; SR-01000075751; EINECS 200-166-6; (o,p)-DDD; Mitotane (JAN/USP/INN); BRN 2056007; AI3-07575; Prestwick_75; Ethane,1-dichloro-; Mitotane (Lysodren); Mitotane [USAN:USP:INN:BAN:JAN]; (2,4'-Dichlorodiphenyl)dichloroethane; PubChem14974; Spectrum_001959; DDD-o,p'; (+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; Spectrum2_000916; Spectrum3_000869; Spectrum4_000709; Spectrum5_002060; C 3010; (o,p')-DDD; SCHEMBL4040; CHEMBL1670; Lopac0_000251; WLN: GYGYR BG&R DG; BSPBio_002517; KBioGR_001237; KBioSS_002513; SPECTRUM330082; MLS001335899; MLS001335900; MLS002152914; MLS002153233; DivK1c_000703; SPBio_000792; CHEBI:6954; GTPL6957; Mitotane, >=98% (HPLC); DTXSID9020372; 2,4'-DDD, analytical standard; HMS502D05; KBio1_000703; KBio2_002505; KBio2_005073; KBio2_007641; KBio3_002017; NINDS_000703; HMS1923K19; HMS2091E07; HMS2232C16; HMS3260D04; HMS3369H10; HMS3655G06; HMS3715H07; HMS3869F13; Pharmakon1600-00330082; BCP11663; 2,4 inverted exclamation marka-DDD; Tox21_110103; Tox21_302804; Tox21_500251; CCG-40014; NSC755849; s1732; 1,2-bis(2,4'-dichlorophenyl)ethane; AKOS006028802; Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)-, (+-)-; Tox21_110103_1; CS-1500; DB00648; LP00251; MCULE-2068358149; NSC-755849; SDCCGSBI-0050239.P006; IDI1_000703; NCGC00015226-02; NCGC00015226-03; NCGC00015226-04; NCGC00015226-05; NCGC00015226-06; NCGC00015226-08; NCGC00015226-09; NCGC00015226-10; NCGC00015226-11; NCGC00015226-12; NCGC00091374-01; NCGC00091374-02; NCGC00091374-03; NCGC00091374-04; NCGC00091374-05; NCGC00091374-06; NCGC00256452-01; NCGC00260936-01; 2,4'-DDD 10 microg/mL in Cyclohexane; AK546750; AS-11690; HY-13690; NCI60_003688; 2,4'-DDD 100 microg/mL in Cyclohexane; SBI-0050239.P004; AB0010565; EU-0100251; FT-0605518; ST51016017; SW199619-3; EN300-37268; 2,4 inverted exclamation marka-DDD;o,p'-DDD; 2,4'-DDD, PESTANAL(R), analytical standard; D00420; W-5031; AB00052337-09; AB00052337_10; 000M850; Q417465; SR-01000075751-1; SR-01000075751-3; SR-01000075751-6; Z425389592; 1-(o-Chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane; 1-[2,2-dichloro-1-(4-chlorophenyl)ethyl]-2-chlorobenzene; Ethane,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene #; Mitotane, United States Pharmacopeia (USP) Reference Standard; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8CI); 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, analytical standard; o,p'-DDD; ; ; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; ; ; Mitotane; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane for diagnostic uses (cancer investigation), >=98% (HPLC); 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, for diagnostic uses (cancer investigation), >=98% (HPLC)
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Adrenocortical carcinoma [ICD-11: 2D11] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| ADMET Property |
Absorption
The oral absorption of drug is 40%
Half-life
The concentration or amount of drug in body reduced by one-half in 18 - 159 days
Metabolism
The drug is metabolized via the hepatic
Click to Show/Hide
|
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C14H10Cl4
|
|||
| PubChem CID | ||||
| Canonical SMILES |
C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl
|
|||
| InChI |
1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
|
|||
| InChIKey |
JWBOIMRXGHLCPP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 53-19-0
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Polymyxin B | Bacillus polymyxa | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | Acinetobacter baumannii ATCC 17978 | Microorganism model | Acinetobacter baumannii | |||
| Acinetobacter baumannii ATCC 19606 | Microorganism model | Acinetobacter baumannii | ||||
| Acinetobacter baumannii FADDI-AB225 | Microorganism model | Acinetobacter baumannii | ||||
| Acinetobacter baumannii FADDI-AB065 | Microorganism model | Acinetobacter baumannii | ||||
| Experimental
Result(s) |
The disruption of the citric acid cycle and inhibition of nucleotide biogenesis are the key metabolic features associated with synergistic bacterial killing by the combination against polymyxin-susceptible and -resistant A. baumannii. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Estrogen receptor (ESR) | Molecule Info | [3] | |
| KEGG Pathway | Estrogen signaling pathway | Click to Show/Hide | ||
| 2 | Prolactin signaling pathway | |||
| 3 | Thyroid hormone signaling pathway | |||
| 4 | Endocrine and other factor-regulated calcium reabsorption | |||
| 5 | Proteoglycans in cancer | |||
| NetPath Pathway | FSH Signaling Pathway | Click to Show/Hide | ||
| 2 | EGFR1 Signaling Pathway | |||
| 3 | RANKL Signaling Pathway | |||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
| 2 | Signaling events mediated by HDAC Class II | |||
| 3 | Plasma membrane estrogen receptor signaling | |||
| 4 | LKB1 signaling events | |||
| 5 | Regulation of Telomerase | |||
| 6 | ATF-2 transcription factor network | |||
| 7 | AP-1 transcription factor network | |||
| 8 | FOXM1 transcription factor network | |||
| 9 | Validated nuclear estrogen receptor alpha network | |||
| 10 | Signaling mediated by p38-alpha and p38-beta | |||
| 11 | FOXA1 transcription factor network | |||
| Reactome | Nuclear signaling by ERBB4 | Click to Show/Hide | ||
| 2 | Nuclear Receptor transcription pathway | |||
| WikiPathways | Estrogen signaling pathway | Click to Show/Hide | ||
| 2 | Nuclear Receptors Meta-Pathway | |||
| 3 | Estrogen Receptor Pathway | |||
| 4 | Signaling by ERBB4 | |||
| 5 | JAK/STAT | |||
| 6 | Integrated Pancreatic Cancer Pathway | |||
| 7 | Leptin signaling pathway | |||
| 8 | miR-targeted genes in muscle cell - TarBase | |||
| 9 | Integrated Breast Cancer Pathway | |||
| 10 | Nuclear Receptors | |||